Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

FATE

Fate Therapeutics Inc

Mar 13 • 04:00PM ET

1.17

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP BLUE SRPT EDIT NTLA CLLS SGMO TVRD VTVT

| Held by: VTI IWM VXF IWN VTWO SCHA PRFZ VHT IWC DFAT

Index	RUT	P/E	-	EPS (ttm)	-1.15	Insider Own	5.30%	Shs Outstand	115.36M	Perf Week	-12.03%
Market Cap	136.03M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	-0.26%	Shs Float	110.10M	Perf Month	0.00%
Enterprise Value	10.22M	PEG	-	EPS next Q	-0.28	Inst Own	70.78%	Short Float	8.69%	Perf Quarter	7.34%
Income	-136.31M	P/S	20.46	EPS this Y	0.58%	Inst Trans	-0.29%	Short Ratio	5.72	Perf Half Y	14.71%
Sales	6.65M	P/B	0.65	EPS next Y	1.94%	ROA	-35.89%	Short Interest	9.56M	Perf YTD	19.07%
Book/sh	1.80	P/C	0.67	EPS next 5Y	-1.00%	ROE	-51.84%	52W High	1.94 -39.69%	Perf Year	24.01%
Cash/sh	1.75	P/FCF	-	EPS past 3/5Y	26.67% 11.42%	ROIC	-48.60%	52W Low	0.66 76.99%	Perf 3Y	-78.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-58.98% -26.71%	Gross Margin	-94.12%	Volatility	8.06% 9.22%	Perf 5Y	-98.76%
Dividend TTM	-	EV/Sales	1.54	EPS Y/Y TTM	30.42%	Oper. Margin	-2222.45%	ATR (14)	0.11	Perf 10Y	-35.71%
Dividend Ex-Date	-	Quick Ratio	5.79	Sales Y/Y TTM	-51.24%	Profit Margin	-2051.08%	RSI (14)	40.53	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.79	EPS Q/Q	38.69%	SMA20	-15.49%	Beta	2.26	Target Price	4.94
Payout	-	Debt/Eq	0.38	Sales Q/Q	-26.40%	SMA50	-4.86%	Rel Volume	1.11	Prev Close	1.17
Employees	161	LT Debt/Eq	0.35	Earnings	Feb 26 BMO	SMA200	-0.91%	Avg Volume	1.67M	Price	1.17
IPO	Oct 01, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.15% 2.42%	Trades		Volume	1,860,010	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-27-25	Upgrade	Wedbush	Neutral → Outperform	$7
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold

Show Previous Ratings

Mar-04-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.84%
Mar-03-26 04:05PM	Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire) -8.67%
10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire)
Feb-26-26 01:30PM	Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.41%
09:15AM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
09:00AM	Loading…
09:00AM	Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-03-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.69%
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
Jan-05-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-08-25 08:00AM	Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs (GlobeNewswire)
Nov-25-25 08:00AM	Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 09:40AM	Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56% -8.40%
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
11:35AM	Loading…
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-26-25 11:30AM	Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy (GlobeNewswire)
Oct-14-25 08:00AM	Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer (GlobeNewswire) +7.91%
Oct-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.22%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire) -5.31%
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +20.69%
04:30PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-11-25 06:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates (Zacks) -5.76% -5.99%
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:57PM	Loading…
Jul-15-25 04:57PM	Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data (Insider Monkey)
07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-03-25 01:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 11:30AM	Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? (Zacks) -9.68%
Jun-11-25 09:00AM	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress (GlobeNewswire) -7.19%
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks) +9.87%
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire) -8.33% +7.44%
May-28-25 11:46PM	Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases (Insider Monkey)
05:54PM	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress (GlobeNewswire)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.54%
04:01PM	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65% -10.69%
Apr-29-25 09:25AM	Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting (GlobeNewswire) -6.40%
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks) +21.17%
Apr-14-25 08:00AM	Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) (GlobeNewswire) -12.80%
Apr-04-25 11:30AM	Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? (Zacks) +10.72%
Apr-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.69%
Mar-05-25 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +14.90%
04:12PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.77%
Feb-17-25 10:00AM	Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-25 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +11.81% +7.75%
Feb-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.40%
Jan-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-24 11:30AM	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks) -11.70%
Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%
08:00AM	Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence (GlobeNewswire)
Nov-12-24 05:20PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.03% -8.82%
04:18PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-09-24 01:30PM	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting (GlobeNewswire)
Nov-08-24 04:01PM	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting (GlobeNewswire) -5.10% +5.79%
Nov-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.58%
Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program (GlobeNewswire)
May-06-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting (GlobeNewswire)
Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire) -5.02%
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TAHL CINDY	See Remarks	Jan 09 '26	Sale	1.06	10,589	11,275	387,081	Jan 12 04:04 PM
Valamehr Bahram	President and CEO	Jan 09 '26	Sale	1.07	5,190	5,557	329,708	Jan 12 04:03 PM
TAHL CINDY	Officer	Jan 09 '26	Proposed Sale	1.06	10,589	11,275		Jan 09 03:08 PM
Valamehr Bahram	Officer	Jan 09 '26	Proposed Sale	1.07	5,190	5,557		Jan 09 03:08 PM
MENDLEIN JOHN	Former Director	Dec 24 '25	Proposed Sale	1.01	38,428	38,881		Dec 29 02:44 PM
TAHL CINDY	See Remarks	Aug 04 '25	Sale	1.06	9,037	9,573	397,670	Aug 05 04:03 PM
Valamehr Bahram	President and CEO	Aug 04 '25	Sale	1.06	14,466	15,396	334,898	Aug 05 04:02 PM
TAHL CINDY	Officer	Aug 04 '25	Proposed Sale	1.06	9,037	9,573		Aug 04 04:56 PM
Valamehr Bahram	Officer	Aug 04 '25	Proposed Sale	1.06	14,466	15,396		Aug 04 04:17 PM

Open in Screener

ADCT

Adc Therapeutics SA

Mar 13 • 04:00PM ET

4.13

-0.22 -5.06 %

Healthcare • Biotechnology • Switzerland • NYSE

ADCT Adc Therapeutics SA daily Stock Chart

Peers: GILD PFE AMGN LLY REGN VRTX JAZZ MRNA BMY INCY

| Held by: IWM IBB IWO VTWO VFMO IWC GWX VTWG IWV RSSL

Index	RUT	P/E	-	EPS (ttm)	-1.20	Insider Own	27.02%	Shs Outstand	125.75M	Perf Week	0.49%
Market Cap	524.69M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	0.00%	Shs Float	92.71M	Perf Month	5.36%
Enterprise Value	702.90M	PEG	-	EPS next Q	-0.20	Inst Own	57.92%	Short Float	4.43%	Perf Quarter	2.99%
Income	-142.62M	P/S	6.45	EPS this Y	28.04%	Inst Trans	3.61%	Short Ratio	4.55	Perf Half Y	24.02%
Sales	81.36M	P/B	-	EPS next Y	21.09%	ROA	-44.16%	Short Interest	4.11M	Perf YTD	17.00%
Book/sh	-1.48	P/C	2.01	EPS next 5Y	-	ROE	-	52W High	4.98 -17.07%	Perf Year	133.33%
Cash/sh	2.06	P/FCF	-	EPS past 3/5Y	17.66% 21.50%	ROIC	-57.01%	52W Low	1.05 293.33%	Perf 3Y	62.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-27.09% -	Gross Margin	90.57%	Volatility	10.93% 7.28%	Perf 5Y	-83.66%
Dividend TTM	-	EV/Sales	8.64	EPS Y/Y TTM	27.54%	Oper. Margin	-133.39%	ATR (14)	0.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.31	Sales Y/Y TTM	14.85%	Profit Margin	-175.31%	RSI (14)	48.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.37	EPS Q/Q	85.39%	SMA20	-2.91%	Beta	1.92	Target Price	8.25
Payout	-	Debt/Eq	-	Sales Q/Q	36.36%	SMA50	4.94%	Rel Volume	0.90	Prev Close	4.35
Employees	193	LT Debt/Eq	-	Earnings	Mar 10 BMO	SMA200	13.53%	Avg Volume	903.29K	Price	4.13
IPO	May 15, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	85.09% 3.40%	Trades		Volume	815,336	Change	-5.06%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Mar-10-26 05:01PM	ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +13.48%
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update (PR Newswire)
Mar-09-26 09:17AM	ADC Therapeutics SA (ADCT) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Mar-03-26 07:15AM	ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 (PR Newswire)
04:05PM	Loading…
Mar-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Feb-24-26 07:15AM	ADC Therapeutics to Participate in March Investor Conferences (PR Newswire)
Feb-23-26 07:15AM	ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement (PR Newswire) +7.56%
Feb-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +8.03%
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-13-26 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Jan-08-26 04:05PM	ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
12:00PM	Loading…
Dec-29-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why (Zacks)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-18-25 01:14AM	RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development (Insider Monkey) +6.27%
Dec-17-25 09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.56%
Dec-15-25 12:00PM	ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-04-25 07:40AM	ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma (TipRanks) -10.38%
Dec-03-25 07:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -14.13%
Dec-02-25 04:05PM	ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial (PR Newswire) +8.49%
Dec-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-18-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-10-25 04:01PM	ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... (GuruFocus.com) -5.70%
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
07:20AM	Loading…
07:20AM	ADC Therapeutics SA (ADCT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.28%
07:15AM	ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 (PR Newswire)
Oct-27-25 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Oct-26-25 06:16AM	ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted (Insider Monkey)
Oct-24-25 08:07AM	H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement (Insider Monkey)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
07:30AM	ADC Therapeutics Announces $60 Million Private Placement (PR Newswire)
Oct-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Sep-29-25 12:56AM	ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion (Insider Monkey) +10.14%
Sep-18-25 10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +6.13%
Aug-27-25 07:15AM	ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 03:07AM	ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... (GuruFocus.com) +5.10%
Aug-12-25 03:00PM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.70%
07:30AM	ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Aug-11-25 07:00PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:34AM	ADC Therapeutics SA (ADCT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 06:10PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 04:05PM	ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 (PR Newswire)
Aug-04-25 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Aug-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Jul-01-25 04:05PM	ADC Therapeutics Makes Grant to New Employee Under Inducement Plan (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-16-25 07:15AM	ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire) -5.59%
Jun-12-25 06:45AM	ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PR Newswire)
06:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress (PR Newswire)
Jun-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +13.59%
May-30-25 05:44AM	AbbVies ADC win shows how pharma can break through in solid tumors (Pharma Voice) +11.55%
May-15-25 07:49AM	ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data (Clinical Trials Arena) -6.63%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-14-25 09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +37.12%
08:00AM	ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
07:45AM	ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire)
May-13-25 09:42AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings (GuruFocus.com)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:15AM	ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 (PR Newswire)
May-01-25 05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +9.77%
07:00AM	ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Apr-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-25 09:00PM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.37%
Mar-27-25 11:17AM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update (PR Newswire)
Mar-25-25 05:30PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Mar-24-25 11:08PM	ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 (SeekingAlpha)
Mar-20-25 07:15AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 (PR Newswire) -6.59%
Feb-03-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -5.95%
Jan-30-25 07:15AM	ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (PR Newswire)
Jan-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Dec-30-24 04:30PM	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma (PR Newswire) -6.40%
Dec-11-24 07:30AM	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -36.21%
Dec-09-24 07:30AM	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Dec-06-24 07:30AM	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial (PR Newswire) +63.02%
Dec-02-24 04:30PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -10.78%
Nov-14-24 02:02AM	BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... (GuruFocus.com) -6.03%
Nov-08-24 01:14PM	ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why (Benzinga)
Nov-07-24 08:50AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.44%
07:30AM	ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update (PR Newswire)
Nov-06-24 07:41AM	What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings (GuruFocus.com)
Nov-05-24 09:47AM	ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting (PR Newswire)
Nov-04-24 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Nov-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-31-24 07:15AM	ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire)

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Open in Screener

STTK

Shattuck Labs Inc

Mar 13 • 04:00PM ET

5.99

-0.14 -2.28 %

Healthcare • Biotechnology • USA • NASD

STTK Shattuck Labs Inc daily Stock Chart

Peers: KURA ADAP FATE DTIL AFMD ALXO HOOK ALDX IMTX

| Held by: VTI VXF DFAS AVSC QQQS TMED DFAC

Index	-	P/E	-	EPS (ttm)	-0.77	Insider Own	21.56%	Shs Outstand	63.28M	Perf Week	0.00%
Market Cap	428.67M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.00%	Shs Float	56.14M	Perf Month	46.45%
Enterprise Value	353.03M	PEG	-	EPS next Q	-0.14	Inst Own	58.37%	Short Float	2.86%	Perf Quarter	85.45%
Income	-48.81M	P/S	428.67	EPS this Y	25.38%	Inst Trans	14.06%	Short Ratio	2.48	Perf Half Y	202.53%
Sales	1.00M	P/B	4.60	EPS next Y	7.84%	ROA	-53.26%	Short Interest	1.60M	Perf YTD	64.11%
Book/sh	1.30	P/C	5.49	EPS next 5Y	7.87%	ROE	-60.25%	52W High	6.25 -4.16%	Perf Year	395.04%
Cash/sh	1.09	P/FCF	-	EPS past 3/5Y	33.69% 4.36%	ROIC	-58.12%	52W Low	0.69 765.42%	Perf 3Y	117.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	15.32% -36.82%	Gross Margin	-268.80%	Volatility	7.99% 8.31%	Perf 5Y	-84.34%
Dividend TTM	-	EV/Sales	353.03	EPS Y/Y TTM	47.92%	Oper. Margin	-5142.70%	ATR (14)	0.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.70	Sales Y/Y TTM	-82.52%	Profit Margin	-4880.90%	RSI (14)	74.45	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	11.70	EPS Q/Q	66.98%	SMA20	26.77%	Beta	1.46	Target Price	10.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	36.56%	Rel Volume	0.55	Prev Close	6.13
Employees	40	LT Debt/Eq	0.02	Earnings	Mar 05 BMO	SMA200	154.69%	Avg Volume	647.83K	Price	5.99
IPO	Oct 09, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.89% -100.00%	Trades		Volume	354,355	Change	-2.28%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-26	Resumed	Needham	Buy	$25
Jan-28-26	Initiated	Piper Sandler	Overweight	$15
Dec-01-25	Upgrade	H.C. Wainwright	Neutral → Buy	$6
Sep-08-25	Initiated	Wedbush	Outperform	$4
Mar-17-25	Initiated	Leerink Partners	Outperform	$4
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-02-24	Downgrade	Citigroup	Buy → Neutral	$8 → $2
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Citigroup	Buy	$36

Show Previous Ratings

Mar-05-26 06:15AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +7.82%
Feb-25-26 08:00AM	Shattuck Labs Announces Participation in Upcoming March Investor Conferences (GlobeNewswire) -5.37%
Feb-06-26 08:30AM	Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire) +5.60%
Jan-05-26 10:50PM	Why Shattuck Labs Stock Soared in December (Motley Fool)
Dec-15-25 04:15PM	Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:26AM	Loading…
Nov-29-25 01:26AM	Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result (Insider Monkey)
Nov-20-25 08:00AM	Shattuck Labs to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-06-25 04:30PM	Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-08-25 12:00PM	What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-02-25 07:51AM	Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel (GlobeNewswire)
Sep-19-25 09:55AM	Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross? (Zacks)
Sep-08-25 05:09PM	Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +21.29% +6.91%
Aug-26-25 06:30AM	Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors (GlobeNewswire)
Aug-21-25 10:17AM	Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) -11.42%
Aug-14-25 06:30AM	Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
10:30AM	Loading…
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +33.30%
06:30AM	Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million (GlobeNewswire)
Jul-02-25 07:00AM	Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
May-01-25 04:20PM	Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +9.20% -7.81%
Apr-02-25 05:00PM	Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.28% -17.34%
Mar-27-25 07:00AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-20-25 09:00AM	Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire)
Feb-13-25 04:30PM	Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire) +5.04% +6.40%
Feb-04-25 07:00AM	Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress (GlobeNewswire)
Jan-06-25 04:59PM	Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.22%
Jan-03-25 07:15AM	Shattuck Labs highlights upcoming key milestones in 2025 (TipRanks) +10.74%
Jan-02-25 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 (GlobeNewswire)
Nov-25-24 07:00AM	Shattuck Labs Announces Participation in Upcoming December Conferences (GlobeNewswire)
Nov-15-24 07:12AM	Shattuck Labs sees cash runway into 2027 (TipRanks) -9.85%
Nov-14-24 07:00AM	Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +12.30%
09:35AM	Loading…
Oct-24-24 09:35AM	Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround (Zacks)
Oct-08-24 09:35AM	After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks) +11.50%
Oct-02-24 11:32AM	Shattuck Labs stock craters following pipeline and job cuts (Pharmaceutical Technology) -34.90%
06:57AM	Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts (TipRanks)
Oct-01-24 12:26PM	Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline (Benzinga) -44.99%
06:30AM	Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway (GlobeNewswire)
Aug-01-24 06:20PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.28%
04:05PM	Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-30-24 05:00PM	Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-01-24 06:00AM	Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-18-24 06:25PM	Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK) (Insider Monkey) -7.83% -9.26%
10:48AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Jun-14-24 01:28PM	Shattuck (STTK) Announces Positive Interim Data on Cancer Drug (Zacks) -9.50%
06:00AM	Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Jun-10-24 07:30AM	Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jun-06-24 07:30AM	Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
May-21-24 09:35AM	After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks)
May-14-24 04:15PM	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire) -18.07%
May-07-24 12:00PM	What Makes Shattuck Labs (STTK) a New Buy Stock (Zacks)
09:55AM	Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? (Zacks)
May-04-24 05:31AM	Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-02-24 09:58PM	STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:25AM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +8.44%
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +10.54%
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.14%
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire) +22.56%
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-09-23 06:01AM	Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:34AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023 (GlobeNewswire)
Dec-13-22 06:51AM	Multiple insiders bought Shattuck Labs, Inc. (NASDAQ:STTK) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-01-22 09:55AM	Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 05:51AM	Shattuck Labs Third Quarter 2022 Earnings: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:30PM	Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -6.75% -5.88%
Nov-07-22 08:00AM	Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-22 11:55AM	Investors in Shattuck Labs (NASDAQ:STTK) have unfortunately lost 86% over the last year (Simply Wall St.)
Nov-03-22 08:30AM	Shattuck Labs Announces Participation in Upcoming November Conferences (GlobeNewswire)
Nov-01-22 04:30PM	Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -8.66%
Oct-12-22 10:04AM	Owning 38% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK), (Simply Wall St.) +10.51%

Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:52 PM
Ashiya Mona	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:50 PM

FATE

Fate Therapeutics Inc

ADCT

Adc Therapeutics SA

STTK

Shattuck Labs Inc

Upgrade your FINVIZ experience